The massive Non-GAAP EPS guidance cut (from ~$5.00 to ~$2.95) overshadows the 32% revenue beat. The shift of a large VOXZOGO international order from Q3 to Q4 and the order timing uncertainty cited in the guidance revision suggest lumpy demand patterns. Watch Q4 2026 results for recovery of that deferred order and any further guidance adjustments.
Drugs in focus
BMRN drug pipeline →BMN 333
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2/3
- Time to market
- If successful through Phase 2/3, potential launch is estimated around 2030 per earlier BioMarin guidance, though the timeline depends on Phase 2/3 results and regulatory interactions.
- Next catalyst
- None dated
What to watchThe next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $55.66entry
- T+1 · 13d ago +2.64%α +0.99% · $57.13
- T+5 · 7d ago +2.64%α +3.23% · $57.13
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition (GALAFOLD and POMBILITI+OPFOLDA) and 12% VOXZOGO growth. GAAP EPS was -$0.63 (vs consensus -$0.11), heavily impacted by $288M in acquired IPR&D charges and $99M in intangible amortization. Non-GAAP EPS was $0.23. Full-year 2026 revenue guidance was lowered to $3.80B-$3.90B (from $3.875B-$3.925B) due to order timing uncertainty, and Non-GAAP EPS guidance was slashed to $2.80-$3.10 (from $4.90-$5.10) reflecting the Alesta acquisition and BMN 450 license charges.
Key Financial Metrics
Key Facts
- Q3 2026 total revenues $1.025B, +32% YoY (from $776M)
- GAAP net loss -$123M vs -$31M YoY; GAAP diluted EPS -$0.63 vs -$0.16 YoY
- Non-GAAP income $45M vs $22M YoY; Non-GAAP diluted EPS $0.23 vs $0.12 YoY
- Full-year 2026 revenue guidance lowered to $3.80B-$3.90B (from $3.875B-$3.925B)
- Full-year 2026 Non-GAAP EPS guidance lowered to $2.80-$3.10 (from $4.90-$5.10), a ~40% cut at midpoint
- Acquired IPR&D charges of $288M in Q3 2026, primarily from Alesta acquisition
- VOXZOGO revenue $245M, +12% YoY; a large international order shifted from Q3 to Q4
- Metabolic Conditions revenue $744M, +44% YoY, driven by GALAFOLD ($152M) and POMBILITI+OPFOLDA ($49M)
- GAAP operating margin -8.0% vs -6.0% YoY; Non-GAAP operating margin 13.4% vs 2.8% YoY
- PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia
Financial Impact
Full-year Non-GAAP EPS guidance cut by ~40% from $5.00 midpoint to $2.95 midpoint, driven by $320M in Alesta-related pre-tax charges and $83M in BMN 450 license charges. Revenue guidance reduced by $50M at midpoint due to order timing uncertainty.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VOXZOGO | $245.0M | +12.0% |
| Metabolic Conditions | $744.0M | +44.0% |
| KUVAN | $23.0M | -4.0% |
| ROCTAVIAN | $1.0M | -67.0% |
Risk Factors
- Full-year Non-GAAP EPS guidance cut by ~40% due to acquisition-related charges and order timing uncertainty
- GAAP net loss widened to -$123M from -$31M, driven by $288M in IPR&D charges and $99M in intangible amortization
- Revenue guidance lowered by $50M at midpoint due to uncertainty in timing of multiple orders from a single international customer
- Large VOXZOGO international order shifted from Q3 to Q4, creating quarterly volatility
- Integration risks from Amicus and Alesta acquisitions; ongoing restructuring costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001048477-26-000021 |
| Document: bmrn-20261102.htm | 0001048477-26-000021 |
| Document: 0001048477-26-000021-index-headers.html | 0001048477-26-000021 |
| Document: 0001048477-26-000021-index.html | 0001048477-26-000021 |
| Document: 0001048477-26-000021.txt | 0001048477-26-000021 |
| 8-K Data (Synthetic) | 0001048477-26-000021 |
Track record
16 reports on BMRN
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Viewing Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers